Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12511997 | 0.91 | CYP1A2 (0.33) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL5250986 | 0.77 | NQO1 (0.38) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL12433418 | 0.76 | ACHE (0.31) | — | |
| SCHEMBL20791700 | 0.75 | — | — | |
| SCHEMBL3456090 | 0.74 | NOS2 (0.43) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL13262610 | 0.74 | PGK1 (0.34) | — | |
| SCHEMBL10752183 | 0.72 | CYP1A2 (0.32) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL21865896 | 0.72 | PON1 (0.36) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL358550 | 0.72 | GABRA1 (0.36) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL1611243 | 0.72 | CYP1A2 (0.32) | CYP1A2CYP2A6TSHRTDP2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3636639-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-7981486-B2 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | JNC CORPORATION (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7846513-B2 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846513-B2 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7740769-B2 | Liquid crystal compound, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20090230356-A1 | COMPOUND HAVING ALKYL ON BENZENE RING, LIQUID CRYSTAL COMPOSITION HAVING THE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE HAVING THE LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1997867-A1 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORPORATION (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-7429411-B2 | Chroman compound, liquid crystal composition including the compound and liquid crystal display element including the liquid crystal composition | CHISSO PETROCHEMICAL CORPORATION (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20070187644-A1 | Liquid crystal compound, liquid crystal composition, and liquid crystal display device | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2007-08-16 | — | — | US | disclosed |
| EP-1818384-A1 | Liquid crystal compound, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090230356-A1 | COMPOUND HAVING ALKYL ON BENZENE RING, LIQUID CRYSTAL COMPOSITION HAVING THE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE HAVING THE LIQUID CRYSTAL COMPOSITION | BRD1, CNOT1, CXCR1 | CYP1A2 155/4885CYP2A6 744/4885TSHR 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.